You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel SCD1 inhibitors for treatment of cancer

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    DESCRIPTION provided by applicant Metastatic clear cell renal cell carcinoma mccRCC is an incurable cancer with a year survival of less than for which novel therapeutic agents need to be developed urgently It is notoriously resistant to chemotherapy and radiation Although molecularly targeted therapies have led to an improvement in survival the benefit is rather limited due to event ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Mobile Intervention Kit to Increase HIV/HCV Testing and Overdose Prevention Training

    SBC: Digital Health Empowerment, Inc            Topic: NIDA

    DESCRIPTION provided by applicant Because many people who inject drugs PWID do not receive adequate information about HIV or HCV testing and prevention or overdose prevention and response training we propose to develop a Mobile Intervention Kit to deliver technology based interventions from a library of theory guided video content The first iteration will address overdose prevention and r ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Targeted Epigenetic Therapy for Triple-Negative Breast Cancer

    SBC: PARKSIDE SCIENTIFIC INC.            Topic: 102

    DESCRIPTIONprovided by applicantTriple negative breast cancerTNBCis one of the most aggressive forms of human cancerand currently has no targeted therapyChemotherapy is the only available treatment for TNBC patientsbut is deleterious and not effective once tumor spreadsTNBC represents a major unmet medical needaboutof breast cancer incidenceswomen worldwide inare TNBCTNBC disproportionally affects ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Engineering stem cells to make mucopolysaccharidosis IIIB

    SBC: Phoenix Nest Inc.            Topic: 107

    DESCRIPTION provided by applicant Sanfilippo disease type B also called mucopolysaccharidosis type III or MPS III is a devastating neuro degenerative genetic disorder of childhood that is fatal There is no cure or effective treatment MPS IIIB is caused by the lack of a lysosomal enzyme called NAGLU alpha N acetylglucosaminidase that is required to degrade heparan sulfate glycosaminoglyca ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Validation of a salivary miRNA diagnostic test for autism spectrum disorder

    SBC: Quadrant Biosciences Inc.            Topic: 105

    Project Summary Abstract Autism spectrum disorder ASD is a continuum of neurodevelopmental characteristics that includes deficits in communication and social interaction as well as restrictive repetitive interests and behaviors ASD is an increasing public health concern with about in American children diagnosed with ASD in a fold increase in prevalence over the past years T ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Smaller, Brighter Probes for Correlative Super-resolution and Electron Microscopy

    SBC: NANOPROBES INC            Topic: NIGMS

    DESCRIPTION provided by applicant We propose new probes for correlative super resolution fluorescence and electron microscopy that use biorthogonal reactions Click SNAP and HALO tags to label targets in living cells To minimize quenching of the fluorophores by the gold particles the small Undecagold gold atoms gold cluster label will be used this has minimal absorption at wavelengt ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Mobile Augmented Screening Tool to Increase Adolescent HIV Testing and Linkage to Care

    SBC: Digital Health Empowerment, Inc            Topic: NICHD

    DESCRIPTION provided by applicant Adolescents face combined problems of increased HIV risk infrequent testing inconsistent linkage to care and a lack of prevention related knowledge We propose to address this by developing a Mobile Augmented Screening MAS tool that will increase youth HIV testing through the use of a tablet based intervention in clinica settings and then use text message ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo syndrome mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is presently no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which pla ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government